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During recent years, treatment of ventricular tachycardia 
has attained increasingly higher levels of sophistication. An 
array of new and more effective antiarrhythmic medications 
has become available and acute drug testing in the electro-
physiology laboratory (I) is rapidly replacing the traditional 
empirical approach, Similarly, innovative procedures of en-
docardial resection (2), encircling ventriculotomy (3) and 
fulguration techniques (4) have been developed, aimed at 
the eradication of arrhythmogenic foci, Because sustained 
ventricular tachycardia is potentially a life-threatening ar-
rhythmia, even the most heroic efforts are frequently nec-
essary and justified. In fact, rather than ventricular fibril-
lation, it is ventricular tachycardia that is progressively being 
recognized as the initiating arrhythmia in the ongoing epi-
demic of sudden cardiac death (5,6). 
Despite the impressive progress, however, successful 
management of ventricular tachycardias remains elusive. 
The reasons for this are numerous. Many patients are re-
fractory to antiarrhythmic medications, and even those who 
are treated with a drug as effective as amiodarone have a I 
year mortality rate of 10 to 20% (7-9). In addition, the side 
effects of the various pharmacologic agents can be serious, 
with noncompliance an ever present possibility, Even more 
worrisome is the increasing evidence that some of the drugs 
in use may actually be arrhythmogenic and aggravate rather 
than prevent the arrhythmia (1O, II). With regard to antiar-
rhythmic surgery, recurrences are still noted in some 20% 
of patients who survive the operation, and the mortality 
associated with the procedure itself is approximately 10% 
(12). This inability to satisfactorily control ventricular 
tachycardia with pharmacologic and surgical means led to 
the development of automatic implantable devices aimed at 
electrically treating arrhythmias (13-15). 
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In this issue of the Journal, Herre et al. (16) report on 
28 patients with recurrent ventricular tachycardia and ven-
tricular fibrillation in whom a pacemaker capable of exter-
nally triggered ventricular stimulation was permanently im-
planted. Twenty-two of these high risk patients were treated 
with conventional and investigational drugs (group I), while 
six underwent mapping-directed endocardial resection (group 
2). Although the device was able to provide demand pacing 
and was used for nonautomatic termination of sustained 
ventricular tachycardias, its main purpose was to perform 
serial, noninvasive, electrophysiologic studies. 
Role of implanted antitachycardia pacemakers. The 
study of Herre et al. (16) raises a number of important and 
provocative questions, The first question deals with the ra-
tionale for implanting a permanent device, the primary pur-
pose of which is to obviate repetitive invasive testing, The 
authors believe that the effort is worthwhile because serial 
electrophysiologic studies are time-consuming, expensive 
and, moreover, fraught with complications. 
Although these points have merit and the very concept 
of noninvasive electrophysiologic testing is an attractive 
one, its chances of becoming broadly accepted could in-
crease markedly if the permanently implanted device were 
also capable of automatically recognizing and treating ven-
tricular tachyarrhythmias, This is not the case with the pace-
makers used in the study of Herre et al. (16), Actually, in 
the present state of the art, no antitachycardia pacemaker is 
capable of achieving this objective, Such devices are unsafe 
because they may accelerate the tachycardia or even induce 
ventricular fibrillation, They are ineffective because they 
are unable to terminate a significant proportion of the tachy-
cardias and are powerless in the presence of ventricular 
fibrillation, They are also unreliable because the individual 
patient's response to this type of treatment is unpredictable, 
It is pertinent to inquire, furthermore, about the clinical 
outcome of patients with episodes of sustained ventricular 
tachycardia whose pharmacologic regimen is guided by se-
rial, noninvasive, electrophysiologic studies, A review of 
the authors' data is revealing, During a mean follow-up 
period of 8.4 months, 9 of the 22 patients in group 1 de-
veloped spontaneous sustained ventricular tachycardia or 
fibrillation, 6 had intolerable side effects and 4 died from 
arrhythmia-related causes. 
Limitations and advantages of antitachycardia de-
vices. Although management of such high risk patients is 
admittedly difficult, these results are not encouraging. It is 
becoming increasingly evident that new approaches are needed 
to overcome the current inability to successfully manage 
sustained ventricular tachycardias. Although the search for 
an ideal drug should continue, improved electronic tech-
nology shows significant promise. In fact, antitachycardia 
pacemakers remain, on both theoretical and clinical grounds, 
an attractive mode of treatment. Despite present limitations, 
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they have a number of inherent advantages such as low 
energy pulses and the absence of patient distress. While the 
recently developed implantable cardioverter-defibrillator is 
safe, effective and aimed at a larger patient group, its high 
energy output is associated with some degree of discomfort 
(17,18). The high energy discharges, moreover, are not 
necessary to terminate the majority of the arrhythmias treated. 
It appears that the optimal solution might be to combine 
in a single device the various electrical treatment modes 
(19). Such an "ideal" device should first attempt to convert 
the arrhythmia with pacing or low energy cardioversion and 
only in case of failure or in the event of acceleration intro-
duce the defibrillating pulse. These technologic develop-
ments are at hand and, when associated with the ability to 
perform serial noninvasive electrophysiologic studies, would 
represent a quantum leap in our ability to manage ventricular 
tachyarrhythmias. 
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